Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
Read More

Incannex Has Engaged Catalent To Develop And Manufacture A cGMP-grade Psilocybin Drug Product For Use In Incannex’s Proprietary Psilocybin-assisted Psychotherapy Drug Development Program And, Potential Wider Commercial Use

Commencing development and manufacture of a psilocybin drug product follows an internal analysis of the interim data from the PsiGAD phase 2 clinical trial, giving Incannex confidence to proceed with formulation

CTLT